SCHEMBL30749013

SCHEMBL30749013

Clc1ncc2c(n1)N(c1ccc(N3CCOCC3)nc1)CC21CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
MAPT P10636 3/20 0.44
HPGD P15428 2/20 0.44
LMNA P02545 2/20 0.44
HTT P42858 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
RECQL P46063 1/20 0.44
KMT2A Q03164 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
OPRM1 P35372 1/20 0.42
OPRL1 P41146 1/20 0.42
CNR2 P34972 7/20 0.40
KCNH2 Q12809 1/20 0.38
ADK P55263 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749034 0.84 ALDH1A1 (0.45) ALDH1A1MAPTHPGDLMNAHTT
SCHEMBL31691240 0.78 ALDH1A1 (0.41) ALDH1A1MAPTHPGDLMNAHTT
SCHEMBL31691440 0.74 PTPN11 (0.34) KCNH2PIK3CA
SCHEMBL30749053 0.72 ALDH1A1 (0.48) ALDH1A1MAPTHPGDLMNAHTT
SCHEMBL30749030 0.70 PIN1 (0.40) MAPTMEN1KMT2ATDP1
SCHEMBL30749019 0.70 PDE4B (0.40) MAPTKCNH2
SCHEMBL30748753 0.70 ALDH1A1 (0.44) ALDH1A1MAPTHPGDLMNAHTT
SCHEMBL30748843 0.69 PDE4B (0.43) MAPTCYP1A2CYP2C9PIK3CA
SCHEMBL30748944 0.67 CCNE1 (0.39) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL1269304 0.66 ALDH1A1 (0.65) ALDH1A1MAPTHPGDLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT ALDH1A1 256/4885MAPT 3029/4885HPGD 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.